You have 9 free searches left this month | to do more

Decitabine

Decitabine is a drug used to treat Acute Myeloid Leukemia, Myelodysplastic Syndrome, Myelodysplastic Syndromes, and other conditions. Decitabine is being actively studied in 79 studies and prior, has been studied in 93.

Top SponsorsTop SitesTop Investigators
M.D. Anderson Cancer CenterUniversity of Texas MD Anderson Cancer CenterHan weidong
National Cancer Institute (NCI)M D Anderson Cancer CenterQifa Liu
Eisai Inc.Roswell Park Cancer InstituteMing Hou
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
U
Recruiting
  • Acute Myeloid Leukemia
  • Chicago, Illinois
    University Of Chicago Medicine Comprehensive Cancer Center
2021-05-12
May 12, 2021
M
Recruiting
  • Recurrent Leukemia
  • Refractory Leukemia
  • Houston, Texas
    M D Anderson Cancer Center
2022-02-02
Feb 2, 2022
T
Recruiting
  • Acute Myeloid Leukemia
  • Complex Karyotype
  • Decitabine
  • Hong Kong, Hong Kong
    The University of Hong Kong
2021-04-26
Apr 26, 2021
F
Terminated
  • Acute Myeloid Leukemia
  • Myelodysplastic Syndromes
  • Philadelphia, Pennsylvania
  • +1 more
2021-02-22
Feb 22, 2021
F
Recruiting
  • Recurrent, Platinum-resistant Ovarian Cancer
  • Decitabine
  • +4 more
  • Milan, Italy
    Fondazione IRCCS Istituto Nazionale dei Tumori
2021-09-03
Sep 3, 2021
R
Recruiting
  • P53 Mutation
  • +3 more
  • Decitabine
  • Arsenic Trioxide
  • Shanghai, Shanghai, China
    Hematological department, Shanghai Institute of Hematology, Ruij
2021-04-20
Apr 20, 2021
N
Active, not recruiting
  • Primary Myelofibrosis
  • Secondary Myelofibrosis
  • Decitabine
  • Laboratory Biomarker Analysis
  • Chicago, Illinois
  • +13 more
2021-11-30
Nov 30, 2021
M
Recruiting
  • Acute Myeloid Leukemia
  • +4 more
  • Decitabine
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
2021-08-10
Aug 10, 2021
B
Recruiting
  • Acute Myeloid Leukemia
  • Recurrent Acute Myeloid Leukemia
  • Los Angeles, California
  • +2 more
2022-03-11
Mar 11, 2022
M
Completed
  • Blasts More Than 20 Percent of Bone Marrow Nucleated Cells
  • +4 more
  • Decitabine
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
2021-03-19
Mar 19, 2021
N
Suspended
  • Acute Myeloid Leukemia
  • +3 more
  • Duarte, California
  • +11 more
2022-02-16
Feb 16, 2022
T
Not yet recruiting
  • Engraft Failure
  • +2 more
  • decitabine
  • +8 more
  • (no location specified)
2021-06-22
Jun 22, 2021
N
Recruiting
  • Previously Treated Myelodysplastic Syndrome
  • +7 more
  • Decitabine
  • Ipilimumab
  • Duarte, California
  • +10 more
2022-03-22
Mar 22, 2022
D
Recruiting
  • Acute Myelogenous Leukemia
  • decitabine
  • DC/AML fusion cells
  • Boston, Massachusetts
  • +1 more
2021-11-15
Nov 15, 2021
B
Active, not recruiting
  • Leukemia, Myeloid, Acute
  • Decitabine
  • BI 836858
  • Jacksonville, Florida
  • +13 more
2022-04-04
Apr 4, 2022
T
Recruiting
  • Acute Myeloid Leukemia
  • +5 more
  • Sacramento, California
  • +2 more
2021-06-09
Jun 9, 2021
R
Recruiting
  • Acute Myeloid Leukemia
  • +7 more
  • New Brunswick, New Jersey
    Rutgers Cancer Institute of New Jersey
2021-08-20
Aug 20, 2021
S
Active, not recruiting
  • AML/MDS
  • Antwerpen, Belgium
  • +36 more
2021-12-29
Dec 29, 2021
R
Withdrawn
  • Castration Levels of Testosterone
  • +8 more
  • Buffalo, New York
    Roswell Park Cancer Institute
2021-03-31
Mar 31, 2021
F
Completed
  • Acute Myeloid Leukemia
  • +2 more
  • Decitabine
  • +2 more
  • Philadelphia, Pennsylvania
  • +1 more
2021-05-18
May 18, 2021
M
Completed
  • Leukemia
  • Houston, Texas
    University of Texas MD Anderson Cancer Center
2020-12-01
Dec 1, 2020
M
Withdrawn
  • Recurrent Acute Myeloid Leukemia
  • Refractory Acute Myeloid Leukemia
  • Alvocidib Hydrochloride
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
2020-11-09
Nov 9, 2020